Himel Barua

As of 2025, our company has become part of Biognosys Group. Biognosys Group delivers high-performance, robust solutions across proteomics, metabolomics, and lipidomics – driving innovation at the forefront of multiomics. Building on the combined strengths of PreOmics, Biognosys, and biocrates, Biognosys Group integrates industry-leading consumables, software, instruments, and CRO services to make advanced mass spectrometry workflows seamless, scalable, and accessible to every laboratory. The Biognosys Group maintains a vendor-neutral strategy, ensuring open and flexible collaboration across the scientific community and broad compatibility of its solutions across the major mass spectrometry platforms. Designed for agility, Biognosys Group technologies can operate independently or within a unified ecosystem, supported by flexible business models and a strong commitment to partnership. The Biognosys Group is an affiliate of Bruker. biocrates is the global leader in mass spectrometry-based quantitative metabolite analysis, with kits and assays covering over 1,000+ metabolites from more than 40 metabolite classes. Our platform combines innovative technology for sample preparation, metabolite identification, and data analysis. The use of quantitative, standardized, and quality-controlled metabolomics methods guarantees robust and reproducible results that are the cornerstones of all clinical research. From just a few microliters of sample material, we can uncover the entire phenotype of an individual and answer a host of questions about systems biology.